Plate Nº 14 · recorded November 15, 2026
Health & Medicine ResearchReported finding
Why Weight-Loss Drugs Fail Some People — and What Can Be Done
GLP-1 drugs like tirzepatide deliver dramatic average weight loss, yet some patients barely respond. Genetics, side effects, diet and exercise explain much of the gap.
By Priya Raman4 min read791 words
In brief
- In one trial, tirzepatide users lost ~20% of body weight on average, semaglutide users ~14%.
- 74.2% of trial participants on GLP-1s reported nausea, diarrhoea or vomiting; 4.5% dropped out.
- A Nature study of nearly 28,000 people found a genetic variant linked to worse nausea and vomiting.
- An estimated 1 in 9 US adults currently take GLP-1 medications for weight loss.
- Only about 1 in 5 people who lose weight by dieting keep it off long term.

An estimated 1 in 9 adults in the United States is currently taking GLP-1 medications for weight loss — yet for a substantial minority, the same drugs that transform one person's body barely work at all. New research and expert commentary now point to a mix of biology, behaviour and circumstance behind this gap, and much of it, researchers say, lies within a patient's control.
The headline results of these drugs are striking. In one recent trial comparing the two leading medications, people taking tirzepatide lost around 20 per cent of their body weight on average, while those taking semaglutide lost around 14 per cent. But the averages conceal a huge range of outcomes: nearly one in five people on tirzepatide lost 30 per cent or more of their body weight, while others showed almost no response at all.
Why do GLP-1 drugs stop working for some people?
GLP-1 drugs — glucagon-like peptide-1 agonists, medicines that mimic a natural gut hormone to reduce hunger and increase feelings of fullness — have generated enormous excitement partly because dieting alone so often fails. According to one major study, only around one in five people who lose weight through dieting keep it off in the long term.
There is no single reason for a poor response, says Prof Roy Taylor, emeritus professor of medicine and metabolism at Newcastle University. "Any drug has variable effects depending on an individual's genetic makeup," he says. "We're all victims of the marvellous polygenic inheritance that we individually have."
In some cases, the drugs do not fail at all — people simply stop taking them before they can take effect, often because of side effects. Nausea, diarrhoea and vomiting are the most common complaints. During one clinical trial published in The New England Journal of Medicine, 74.2 per cent of participants on GLP-1s experienced such symptoms, and 4.5 per cent dropped out because they were so severe. Most reported the side effects just after an injection or when increasing the dose.
Genetics may compound the problem. A recent study in Nature of nearly 28,000 people taking GLP-1 drugs found that some carried a genetic variant making them more likely to experience nausea and vomiting. Even so, Taylor argues that with an appropriate dose and careful clinical guidance, the drugs should overcome genetic obstacles.
What role do diet, exercise and sleep play?
Patients are often told to maintain a healthy diet alongside treatment — and for good reason. Those who continue eating highly calorific foods will see only a marginal impact from the drugs.
Exercise matters too. A 2024 study in eClinicalMedicine found that people taking GLP-1 drugs lost more weight, and were more likely to keep it off long term, when they combined treatment with supervised exercise rather than relying on the drugs alone.
Sex may also influence outcomes. A study in Diabetes Care found that women lost more weight than men while taking the drugs — possibly because women naturally produce more of the body's own GLP-1 hormone, and because oestrogen increases the body's sensitivity to insulin (the hormone that regulates blood sugar). Taylor, however, is sceptical. "I wouldn't be surprised if it was slightly less effective in men," he says, but sex is likely to play "only a minor role".
Sleep deprivation could also be a factor: one study found it exerts a "mild, but discernible effect" on GLP-1 concentrations in healthy men. Taylor again cautions against drawing a direct line. "The effect of sleep on the body in terms of metabolic effects is trivial," he argues. In heavier individuals, poor sleep is often caused by excess weight — fat around the throat triggering snoring or even sleep apnoea (interrupted breathing during sleep) — rather than the reverse. "If a person injects the GLP-1s consistently, there will probably be just an improvement in sleep," he says.
How can patients improve their odds?
For an unfortunate minority, evidence suggests no change in dosage will make a difference. For everyone else facing controllable obstacles, the first step is honest communication. Doctors must explain how the drugs work and warn that nausea is likely at first — and that it fades with continued use, Taylor says. This is especially important for the many people taking the drugs without medical supervision.
"If this is not explained — and especially so if people are taking these drugs without medical supervision, as many people are — then this is a really potent issue," he said. "Individuals vary in their response to drugs," but it is the doctor's responsibility to "ensure that people are aware of what's about to happen."
The message, in short: the injection is only part of the equation.
via sciencefocus.com (Source)
More from Priya Raman
Show full bio
Senior reporter covering people, launches and day-to-day practice in general science news at SciBeat.
395 articles
Nearby plates
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation
- GLP-1 Weight-Loss Drugs Work Similarly Across Age, Race, and Weight
- Semaglutide and Tirzepatide: Heart Outcomes Compared in Real-World Study
- Stopping GLP-1 Drugs: Five Evidence-Based Ways to Keep the Weight Off
- Amylin Drug Petrelintide Delivers Over 10% Weight Loss